Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies.
ABSTRACT The difference of cardiovascular effects between rosiglitazone and pioglitazone treatment for diabetic patients has not been thoroughly studied. We performed a meta-analysis to compare the risk of cardiovascular adverse effects in patients with type 2 diabetes treated with rosiglitazone compared to pioglitazone.
The Cochrane Library, PubMed, and Embase were searched to identify retrospective cohort studies assessing cardiovascular outcomes with rosiglitazone and pioglitazone. Meta-analysis of retrospective cohort studies was conducted using RevMan 5.0 software to calculate risk ratios.
Of the 74 references identified, eight studies involving 945 286 patients fit the inclusion criteria for the analysis. The results of meta-analyses showed that, compared with pioglitazone, rosiglitazone therapy significantly increased the risk of myocardial infarction (risk ratios (RR) 1.17, 95% confidence interval (CI) 1.04 - 1.32; P = 0.01), the risk of heart failure (RR 1.18, 95%CI 1.02 - 1.36; P = 0.03), and total mortality (RR 1.13, 95%CI 1.08 - 1.20; P < 0.000 01).
Compared with pioglitazone, rosiglitazone was associated with an increased risk of myocardial infarction, heart failure, and all-cause mortality in diabetic patients.
SourceAvailable from: Andrea V Margulis[Show abstract] [Hide abstract]
ABSTRACT: Patients with type 2 diabetes mellitus (T2DM) are at high risk of heart failure. A summary of the effects of blood glucose-lowering drugs other than glitazones on the risk of heart failure in routine clinical practice is lacking. The objective of this study was to conduct a systematic review and meta-analysis of observational studies on the risk of heart failure when using blood glucose-lowering drugs.BMC Cardiovascular Disorders 09/2014; 14(1):129. DOI:10.1186/1471-2261-14-129 · 1.50 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: The amelioration in hyperglycaemia and insulin resistance of fucoidan from sea cucumber can be speculated due to these effects of fucoidan from marine phaeophyta. We examined the effect of fucoidan from Acaudina molpadioides (Am-FUC) on anti-hyperglycaemia and improvement in insulin resistance in high-fat high-sucrose diet-induced insulin resistant mice. Results showed that Am-FUC significantly reduced blood glucose, insulin, leptin, resistin, and TNF-α levels, and increased adiponectin and hepatic glycogen contents. Am-FUC improved glucose metabolism via an increase in hexokinase and pyruvate kinase activities, and a reduction in glycogen phosphorylase and glucose-6-phosphates activities. Am-FUC enhanced glucose transport through successively activated insulin signalling cascadeinduced GLUT4 translocation. Am-FUC also enhanced the effects of rosiglitazone. No signs of toxicity were observed in acute oral toxicity study. It indicates that Am-FUC acutely reduces blood glucose level and improves insulin resistance via normalization of cytokines and glucose metabolism-related enzyme activities and up-regulation of the PKB/GLUT4 pathway.Journal of Functional Foods 09/2014; 10:128–138. DOI:10.1016/j.jff.2014.05.012 · 4.48 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Animal models of diabetes coupled with proteome profiling have great potential not only to provide important insights to the mechanisms of the development of diabetes, its complications, but also help to identify new protein potential candidate biomarkers and to support for therapy of the disease. The aim of this study is to profile thermostable proteins in diabetic cardiovascular rat plasma. Diabetic cardiovascular rats were induced by high-fat diet and low-dose streptozotocin (STZ) injection. Diabetic cardiovascular rat plasma has been used for thermostable pre-fractionation. The thermostable proteins have been separated and identified by using two-dimensional electrophoresis and nanoLC-MS/MS. At least five proteins (fibrinogen alpha chain, antithrombin-III precursor, angiotensinogen 1, haptoglobin, haptoglobin alpha 1S) were significantly up-regulated and three proteins (apolipoprotein A-IV, apolipoprotein E, apolipoprotein A-I) were down-regulated in diabetic cardiovascular samples, in which, the concentration of the antithrombin-III increased most (2.87 folds), followed by fibrinogen alpha chain (2.02 folds), angiotensinogen 1 (1.42 folds), haptoglobin (1.97 folds), haptoglobin alpha 1S (1.59 folds), while apolipoprotein A-I decreased 1.37 folds, apolipoprotein A-IV and apolipoprotein E were not detected in diabetic cardiovascular rat’s plasma, as compared with that of the control rats. The different expression level of thermostable proteins in STZ rat plasma could give us new and important evidence for the understanding of the mechanism of diabetic cardiovascular diseases02/2014; 4(1):9-14. DOI:10.5963/LSMR0401002